Description

Ticilimumab (Tremelimumab) is a fully human monoclonal antibody targeting CTLA-4, designed to block inhibitory T-cell signals and enhance anti-tumor immune responses. This compound is a critical active pharmaceutical ingredient (API) for the development of advanced immunotherapies in oncology. It is essential for pharmaceutical manufacturers and research institutions focused on creating next-generation treatments for cancers such as mesothelioma, non-small cell lung cancer, and hepatocellular carcinoma.

Application

• Primary Active Pharmaceutical Ingredient (API) for immuno-oncology therapeutics targeting CTLA-4.
• Clinical and preclinical research into combination cancer therapies, often paired with PD-1/PD-L1 inhibitors.
• Manufacturing of biologic drug substances for the treatment of mesothelioma, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC).
• Reference standard for analytical method development and quality control in biopharmaceutical production.
• Investigational use in studies exploring immune checkpoint blockade mechanisms and efficacy.
• Component in formulation development for stable injectable biologic products.

Basic Information

Product Name	Ticilimumab (Tremelimumab)
CAS No.	745013-59-6
Molecular Formula	C6428H9902N1694O2020S44
Molecular Weight	Approx. 144 kDa
Synonyms	Tremelimumab; Ticilimumab; Anti-CTLA-4 monoclonal antibody; CP-675,206; CP 675206; Immunoglobulin G2, anti-(human cytotoxic T-lymphocyte-associated antigen 4) (human-mouse monoclonal CP-675206 γ2-chain), disulfide with human-mouse monoclonal CP-675206 light chain, dimer; CTLA-4 blocking antibody
EINECS	Contact for details

Quality Control

Our Ticilimumab (Tremelimumab) is manufactured under strict quality systems suitable for pharmaceutical development. Each batch is subjected to a comprehensive battery of analytical tests to ensure identity, purity, potency, and safety, aligning with ICH Q6B guidelines for biotechnological products. A Certificate of Analysis (COA) detailing specifications such as purity (by SEC-HPLC and CE-SDS), bioactivity (cell-based assay), endotoxin levels, and host cell protein content is provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized powder at -20°C or below. Reconstituted or liquid formulations should be stored at 2-8°C for short-term use. This product is hygroscopic (moisture-sensitive); ensure containers are sealed under controlled, dry conditions to maintain stability and prevent degradation.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear solution
Identification (HPLC/MS)	Conforms to reference standard
Purity (SEC-HPLC)	≥ 98.0% (Monomer)
Purity (CE-SDS, reduced)	≥ 95.0% (Intact IgG)
Protein Content (UV A280)	95.0 - 105.0% of label claim
Potency (Cell-based Bioassay)	90.0 - 115.0% of reference
Endotoxin	< 1.0 EU/mg
Host Cell Protein (HCP)	< 100 ppm
Residual DNA	< 10 pg/mg
pH	6.0 - 7.5 (for solution)

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.